https://orcid.org/0000-0002-9932-8879
References
- Baird LG, Banken R, Eichler H-G, et al. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014;96(5):559–571..
- Jeong H. Korea’s National Health Insurance—lessons from the past three decades. Health Aff. 2011;30(1):136–144.
- Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009;24(1):63–71.
- Ministry of Health and Welfare [Internet]. Policy measures to optimize drug expenditure [Press release]. 2006 Dec 27. [Cited 2020 Jan 6] Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=39921
- Park SE, Lim SH, Choi HW, et al. Evaluation on the first 2 years of the positive list system in South Korea. Health Policy. 2012;104(1):32–39.
- Bae E-Y, Hong J-M, Kwon H-Y, et al., Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy. 120(6): 612–620. 2016. .
- Kim H-J, Park H-J, Ko S-K. Health technology assessment and decision making: art of scientific interpretation. J Health Tech Assess.. 2013;1:86–92.
- Lee JY, Cho YM, Kim ST, et al. Methods on improvement of accessibility for rare disease treatments: providers’ perspective. J Health Tech Assess. 2014;2(1):35–42.
- Bae EY. Positive list system in Korea: issues and challenges. J Health Tech Assess. 2013;1:43–50.
- Bae E. Drug reimbursement decisions in Korea, Australia, and Canada. Korean J Health Econ Policy. 2011;17:1–21.
- Clement FM, Harris A, Li JJ, et al. using effectiveness and cost-effectiveness to make drug coverage decisions. JAMA. 2009;302(13):1437–1443.
- Korean Society of Medical Oncology (Korea Cancer Care Alliance). Current status of cancer care coverage in Korea [Internet]. 2016. [Cited 2020 Jan 6] Available from: http://www.ksmo.or.kr/file/cancer_2016.pdf
- Kim S, Cho H, Yoo H, et al. The analysis of new drug reimbursement decision making in South Korea after the introduction of Positive Listing System. Value Health. 2017;20(9):A676.
- Bae EY, Lee EK. Pharmacoeconomic guidelines and their implementation in the positive list system in South Korea. Value Health. 2009;12(Supp3):S36–41.
- Bae S, Lee S, Bae EY, et al. Korean guidelines for pharmacoeconomic evaluation (second and updated version): consensus and compromise. PharmacoEconomics. 2013;31(4):257–267.
- Minister of Health and Welfare. Regulation for criteria for providing reimbursed services in the National Health Insurance. Seoul: Ministry of Health and Welfare; 2017.
- Ministry of Health and Welfare. Criteria for decision or adjustment on drugs. Seoul: Ministry of Health and Welfare; 2017.
- President of National Health Insurance Service. Guidelines for Negotiation on Drug Prices. Seoul: National Health Insurance Service; 2016.
- President of Health Insurance Review and Assessment Service. Regulation of evaluation criteria, procedures, and etc for reimbursement determinations of drugs. Seoul: Health Insurance Review and Assessment Service; 2016.
- Ministry of Health and Welfare [Internet]. Regulation introduction of risk sharing agreement [Press release]. 2013 Sept. [Cited 2020 Jan 6] Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=290962&page=1
- Ministry of Health and Welfare [Internet]. Regulation introduction of pharmacoeconomics evaluation exemption [Announcement]. 2014 Dec 16. [Cited 2020 Jan 6] Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=315539&page=1
- Health Insurance Review and Assessment Service (KOR) [Internet]. Result of drug reimbursement evaluation committee. [Cited 2020 Jan 6] Available from: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA03001404000023.
- Wahhlster P, Scahill S, Lu CY, et al. Barriers to access and use of high cost medicines: A review. Health Policy Technol. 2015;20(3):191–214.
- Kanters TA, Redekop WK, Hakkaart L. International differences in patient access to ultra-orphan drugs. Health Policy Technol. 2018;7(1):57–64.
- Akehurst R, Abadie E, Renaudin N, et al. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20(1):67–76.
- Wonder M. 2014. Reimbursement success rates and timelines for new medicines for cancer; an international comparison. Cronulla, AU: Wonder Drug Consulting Pty Ltd. Available from: https://medicinesaustralia.com.au/wp-content/uploads/sites/52/2013/07/140323_OIT_Wonder-Report_FINAL.pdf